These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2472126)

  • 1. Effective pharmacotherapy of alcoholic amnestic disorder with fluvoxamine. Preliminary findings.
    Martin PR; Adinoff B; Eckardt MJ; Stapleton JM; Bone GA; Rubinow DR; Lane EA; Linnoila M
    Arch Gen Psychiatry; 1989 Jul; 46(7):617-21. PubMed ID: 2472126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of alcoholic organic brain syndrome with the serotonin reuptake inhibitor fluvoxamine: a preliminary study.
    Stapleton JM; Eckardt MJ; Martin P; Adinoff B; Roehrich L; Bone G; Rubinow D; Linnoila M
    Adv Alcohol Subst Abuse; 1988; 7(3-4):47-51. PubMed ID: 2464912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory improvement in Korsakoff's disease with fluvoxamine.
    McEntee WJ; Mair RG
    Arch Gen Psychiatry; 1990 Oct; 47(10):978-9. PubMed ID: 2121117
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluvoxamine treatment of alcoholic amnestic disorder.
    Martin PR; Adinoff B; Lane E; Stapleton JM; Bone GA; Weingartner H; Linnoila M; Eckardt MJ
    Eur Neuropsychopharmacol; 1995 Mar; 5(1):27-33. PubMed ID: 7542052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fluvoxamine treatment on cognitive functioning in the alcoholic Korsakoff syndrome.
    O'Carroll RE; Moffoot AP; Ebmeier KP; Goodwin GM
    Psychopharmacology (Berl); 1994 Sep; 116(1):85-8. PubMed ID: 7862935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurochemical pathology in Korsakoff's psychosis: implications for other cognitive disorders.
    McEntee WJ; Mair RG; Langlais PJ
    Neurology; 1984 May; 34(5):648-52. PubMed ID: 6200802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memory impairment in Korsakoff's psychosis: a correlation with brain noradrenergic activity.
    McEntee WJ; Mair RG
    Science; 1978 Nov; 202(4370):905-7. PubMed ID: 715450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.
    Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J
    Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central nervous system catecholamine metabolism in Korsakoff's psychosis.
    Martin PR; Weingartner H; Gordon EK; Burns RS; Linnoila M; Kopin IJ; Ebert MH
    Ann Neurol; 1984 Feb; 15(2):184-7. PubMed ID: 6200058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal sensory discrimination deficits in Korsakoff's psychosis.
    Mair RG; Doty RL; Kelly KM; Wilson CS; Langlais PJ; McEntee WJ; Vollmecke TA
    Neuropsychologia; 1986; 24(6):831-9. PubMed ID: 2433640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic resonance imaging in Alzheimer's disease, multi-infarct dementia, alcoholic dementia and Korsakoff's psychosis.
    Besson JA; Crawford JR; Parker DM; Smith FW
    Acta Psychiatr Scand; 1989 Nov; 80(5):451-8. PubMed ID: 2596343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Korsakoff's syndrome, cognition and clonidine.
    O'Carroll RE; Moffoot A; Ebmeier KP; Murray C; Goodwin GM
    Psychol Med; 1993 May; 23(2):341-7. PubMed ID: 8332651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.
    Goodman WK; Price LH; Delgado PL; Palumbo J; Krystal JH; Nagy LM; Rasmussen SA; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1990 Jun; 47(6):577-85. PubMed ID: 2112374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine.
    Nathan RS; Perel JM; Pollock BG; Kupfer DJ
    J Clin Psychiatry; 1990 Sep; 51(9):367-72. PubMed ID: 2120201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noradrenergic and cholinergic agents in Korsakoff's syndrome.
    O'Donnell VM; Pitts WM; Fann WE
    Clin Neuropharmacol; 1986; 9(1):65-70. PubMed ID: 3548954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memory enhancement in Korsakoff's psychosis by clonidine: further evidence for a noradrenergic deficit.
    McEntee WJ; Mair RG
    Ann Neurol; 1980 May; 7(5):466-70. PubMed ID: 6994586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced lumbar CSF somatostatin levels in Alzheimer's disease.
    Wood PL; Etienne P; Lal S; Gauthier S; Cajal S; Nair NP
    Life Sci; 1982 Nov; 31(19):2073-9. PubMed ID: 6184590
    [No Abstract]   [Full Text] [Related]  

  • 18. Visuoperceptive deficits in long-term alcoholics and alcoholics with Korsakoff's psychosis.
    Kapur N; Butters N
    J Stud Alcohol; 1977 Nov; 38(11):2025-35. PubMed ID: 592828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
    McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
    J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memory of alcoholic patients, including Korsakoff's, tested with a Brown-Peterson paradigm.
    Kessler J; Markowitsch HJ; Bast-Kessler C
    Arch Psychol (Frankf); 1987; 139(2):115-32. PubMed ID: 3442472
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.